Monogram Biosciences
Monogram Biosciences is recorded as a service provider in 23 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 23 trials · Latest update first
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Sponsor Sanofi Vaccines US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study)
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN)
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, multi-center, randomized, parallel-group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide once daily for virologic suppression and maintenance in antiretroviral therapy naive adults living with HIV
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
C3731003 Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19
Sponsor Gilead Sciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- All 3 participants were enrolled at United States sites, with 2 participants in Cohort 1 and 1 in Cohort 2.
- Only 3 participants completed the prematurely stopped trial, so protocol-specified analyses could not be performed.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People with HIV-1
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents with HIV who are Virologically Suppressed on ART
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection.
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Sponsor Myokardia Inc.
- Start (EU)
- Latest update
- Estimated end
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE Study)
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV 1
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed
Sponsor Viiv Healthcare UK Limited
- Start (EU)
- Latest update
- Estimated end
C3391003 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Monogram Biosciences?
The 2026-10-09 snapshot links Monogram Biosciences to 23 distinct CTIS trials. Recorded services include Laboratory services, Genotypic resistance testing, Genotyping, HIV resistance testing, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Monogram Biosciences?
The most frequently recorded therapeutic areas are Infectious Disease, Blood Disorders, Respiratory. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Monogram Biosciences conducted?
The linked trials record locations in 18 countries, including Spain, France, Germany, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Monogram Biosciences delivered services.
What can this page tell me about Monogram Biosciences's trial experience?
Browse 23 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Monogram Biosciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Monogram Biosciences Inc.